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(age, BMI and presence of amiodarone or metabolic inducers) and 
genetic variables (genetic variants in CYP2C9, VKORC1, CYP4F2 
and APOE genes). Our objective was to test the performance of the 
EU-PACT algorithm in our cohort of patients. Assess the influence of 
factors included in our algorithm but not considered in the EU-PACT 
algorithm, specifically CYP4F2 and APOE variants, and concomitant 
use of metabolic inducers.
Patients (or Materials) and Methods: We evaluated the performance 
of the EU-PACT algorithm in our cohort (HULP) using coefficient 
of determination (R2). To investigate the contribution of vatiants in 
CYP4F2 and APOE, and concomitant metabolic inducers, we com-
pared the real acenocoumarol doses of patients with these variables 
and those doses predicted by both models. A third model was built 
using as independent variables the dose predicted using EUPACT 
algorithm in our cohort, APOE and CYP4F2 variants, and concomi-
tant metabolic inducers. Paired McNemar’s test was used to compare 
both R2.
Results: Variability explained by the EU-PACT’s algorithm when 
applied to our (HULP) cohort was 44.4%. The real mean dose in 
patients with at least 1 of the evaluated variables (CYP4F2, APOE 
variants or metabolic inducers) was 19.3 (8.1) mg/week while the 
dose calculated by the HULP-algorithm was almost the same (19.0 
[5.4] mg/week) and the EU-PACT’s model underestimates almost 3 
mg (16.0 [6.2] mg/week), P < 0.001. The third model, evaluating 
the contribution of CYP4F2 and APOE variants and concomitant 
metabolic inducers, is able to increase the R2 from a 44.4% observed 
with the EU-PACT algorithm to 47.5% (P < 0.05).
Conclusion: EU-PACT shows a reasonable performance in an inde-
pendent cohort with VTD. Inclusion of other known genes involved 
in high dose requirements as CYP4F2 and ApoE and enzyme inducer 
drugs, all included in HULP algorithm, seems to improve prediction 
in acenocoumarol dosing.
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Introduction: Eating behavior has been shown to be affected by the 
brain-derived neurotrophic factor (BDNF). In the present work, we 
have aimed to investigate whether BDNF genetic variability may 
influence physiological and psychopathological features in patients 
with eating disorders (ED) and/or modulate the risk for the disorder.
Patients (or Materials) and Methods: One hundred twenty unrelated 
female patients with anorexia or bulimia nervosa (AN, BN) and 125 
healthy controls were genotyped for BDNF single nucleotide poly-
morphisms (SNPs). Associated psychopathological characteristics 
were assessed by the EDI-2 and SCL-90R inventories.
Results: With regard to physiological parameters, the rs16917237 
TT genotype was associated with increased minimum weight (60.6 
[19.3] vs 50.4 [11.9] kg; P < 0.05) and BMI (23.3 [7.9] vs 19.3 
[4.1]; P < 0.05) in the whole population of patients with ED. The 
risk study showed that only the rs11030119 AA genotype increased 
the risk for AN (OR = 5.23 [1.32–20.98], p = 0.02), although the 
association lost significance after Bonferroni correction. AN patients 
who harbored the -270CC genotype scored higher than CT carriers 
in the Interpersonal Distrust scale of the EDI-2 questionnaire (6.9 
[4.4] vs 2.9 [3.6]; Bonferroni P < 0.05). In the same manner, car-
riers of rs10835210 CC wildtype genotype showed higher scores 
for the Drive for Thinness scale (13.5 [5.0] vs 9.6 [6.0] for patients 
with the variant allele; Bonferroni P < 0.05). Finally, the haplotype 
study showed that 2 combinations (haplotypes *4 and *7) showed 
significantly higher scores in several scales of the EDI-2 and SCL-90R 
inventories than those with the most common haplotype *1. 
Table.  Descriptive and clinical variables of patients with anorexia 
nervosa (AN) or bulimia nervosa (BN) and healthy controls. 
Mean (SD) values are shown.
AN BN Controls P
Age, years 25.4 (7.67) 26.88 (6.88) 22.18 (6.13) NS
Height, m 1.61 (0.07) 1.61 (0.05) 1.62 (0.05) NS
Weight, kg 45.56 (6.44) 60.16 (3.84) 58.1 (9.33) < 0.05a
BMI, kg/m2 17.6 (2.31) 22.88 (5.27) 22.13 (3.45) < 0.05a
Age at onset, 17.16 (5.07) 19.57 (6.7)
Mean duration of 
illness, y
19.63 (7.25) 19.62 (5.9)
Total EDI-2 score 87.46 (42.67) 115.64 (41.88)
GSI (SCL-90R) score 1.54 (0.81) 1.97 (0.89)
PST (SCL-90R) score 60.72 (20.7) 71.02 (17.8)
PSDI (SCL-90R) score 2.17 (0.75) 2.41 (0.57)
Conclusion: Variability in the BDNF gene locus may contribute to 
psychopathological features that are commonly found in ED patients.
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Introduction: Acenocoumarol is an oral anticoagulant of the cou-
marin type. These anticoagulants have a narrow therapeutic index 
and are characterized by a large interpatient variability that can be 
explained by numerous factors, including genetic factors. Dose vari-
ability due to polymorphisms in the VKORC1 and the CYP2C9 genes 
has been well characterized. The aim of our study was to investigate 
the potential association between ABCB1 polymorphisms and the 
time-to-achieve stability during acenocoumarol treatment.
Patients (or Materials) and Methods: We conducted a prospective 
observational study on 115 hospitalized patients, aged 18 years and 
over and starting acenocoumarol. Collected data included sex, age, 
anticoagulant indication, INR measurements, acenocoumarol doses, 
comorbidities, comedications, and genotype (ABCB1 c.3435C> T 
and c.2677G> T/A). Patients were followed from the date of the first 
acenocoumarol administration until time-to-achieve stability or the 
end of the observation period of 35 days. Time-to achieve stability 
was defined as the first 3 consecutive INR measurements within the 
